The GW Cancer Center is proud of its physician scientists and their commitment to medical research. These clinical studies are designed to add to the medical knowledge base and relate to the treatment, diagnosis, and prevention of diseases or conditions. The studies listed below are currently open to new patients. To learn more or enroll in a study, please call the phone number listed under "Contact Info" for the study of interest.

Clinical Program Title Description
Cutaneous Oncology Program A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II TO IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)

Primary outcome measures:
Pathologic complete response (pCR) rate assessed by independent central pathology review [Time Frame: Up to 12 weeks]

Secondary outcome measures:

  1. Major pathologic response (mPR) rate assessed by independent central pathology review [Time Frame: Up to 12 weeks]
  2. pCR rate assessed by local pathology review [Time Frame: Up to 12 weeks]
  3. mPR rate assessed by local pathology review [Time Frame: Up to 12 weeks]
  4. Objective response rate (ORR) prior to surgery, according to investigator assessment using RECIST 1.1 [Time Frame: Up to 12 weeks]
  5. Event free survival (EFS) [Time Frame: Up to 50 months]
  6. Disease free survival (DFS) [Time Frame: Up to 47 months]
  7. Overall survival (OS) [Time Frame: Up to 50 months]
  8. Incidence of adverse events (AEs) [Time Frame: Up to 52 months]
  9. Incidence of serious adverse events (SAEs) [Time Frame: Up to 52 months
  10. ...
Cutaneous Oncology Program A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma

The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT).